Biogen (NASDAQ: BIIB) Stock Target Raised by RBC Capital Amidst Pipeline Challenges

  • RBC Capital analyst Brian Abrahams raised the price target for Biogen (NASDAQ: BIIB) to $227.00, suggesting a potential 17.57% increase.
  • Despite this optimistic outlook, Biogen faced setbacks with its drug pipeline, including the discontinuation of its Parkinson's drug BIIB122 and a missed primary goal for its Alzheimer's treatment diranersen.
  • The positive analyst view may be supported by strong first-quarter earnings and the planned acquisition of Apellis Pharmaceuticals (NASDAQ: APLS) for $41.00 per share.

Biogen is a leading biotechnology company focused on developing therapies for neurological and neurodegenerative diseases. On May 27, 2026, RBC Capital analyst Brian Abrahams raised the stock price target for Biogen to $227.00. This new target suggests a potential 17.57% increase from the stock's price of $193.08 at the time of the announcement, offering a positive Biogen stock forecast.

This optimistic outlook comes despite recent setbacks in the company's drug pipeline. Biogen and its partner, Denali Therapeutics (NASDAQ: DNLI), announced they will stop developing their Parkinson's drug, BIIB122. As highlighted by Reuters, this decision follows the drug's failure to meet its main goal in a mid-to-late stage study, impacting biopharma investment analysis.

The company also faced a challenge with its experimental Alzheimer's treatment, diranersen. As noted by MarketBeat, the drug's Phase 2 study missed its primary goal. These trial failures are significant events, as new drug approvals are critical for biotechnology firms and are overseen by bodies like the U.S. Food & Drug Administration (FDA).

Despite these trial misses, the analyst's positive view may be supported by other company activities. Biogen had a strong first-quarter earnings report. It also plans to acquire Apellis Pharmaceuticals for $41.00 per share, which will add two commercialized drugs for rare diseases and immunology to its portfolio, strengthening Biogen's market position and future stock performance.

Currently, Biogen stock trades at $193.08, with a market capitalization of about $28.51 billion. The stock has seen a 52-week trading range between $121.05 and $205.97. Market capitalization is the total value of a company's shares and is found by multiplying the stock price by the number of shares.

About the Author
Andrew Wynn

Market news and analyst rating coverage

Andrew Wynn writes market news and analyst-rating coverage for the FMP blog, tracking price-target revisions, broker upgrades and downgrades, and earnings developments across U.S. equities. His posts distill fast-moving market events into clear, factual summaries grounded in financial data.

Related

Financial data for every need

Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions — all accessible via API.

Create Free Account